Joshua Ruch Acquires Additional Shares in GeneDx Holdings

On June 18, 2026, Joshua Ruch purchased 4,248 shares of GeneDx Holdings Corp. (NasdaqGS: WGS). The transaction didn't specify a price per share or total value. This insider activity was not part of a pre-planned trading program.

Insider Buying and Selling at GeneDx Holdings Corp.

Several insiders were active at GeneDx Holdings Corp. on June 18, 2026. Joshua Ruch bought 4,248 shares, while Jason Ryan and Keith Meister each sold 3,576 shares. Eli Casdin and Thomas Fuchs also acquired 4,248 shares each. None of these transactions were made under a Rule 10b5-1 plan.

Other Institutional Activity in GeneDx Holdings

Several institutional investors adjusted their positions in GeneDx Holdings. Corvex Management LP increased its holdings by 169,520 shares, reaching 3,228,149 shares valued at around $207.3 million, a 5.5% increase. Westfield Capital Management Co LP added 350,847 shares, resulting in a 34.5% increase to 1,369,108 shares worth approximately $87.9 million. Goldman Sachs Group Inc increased its position by 114,478 shares, a 9.4% increase, ending with 1,334,980 shares valued at $85.7 million. Meanwhile, BlackRock, Inc. reduced its holdings by 9,386 shares, a 0.6% decrease, holding 1,550,708 shares worth about $99.6 million.

GeneDx Holdings Corp. Stock Down 6.1%

Shares of GeneDx Holdings Corp. (NasdaqGS: WGS) traded near $55.42 on Wednesday. The company, with a market cap of approximately $1.65 billion, has a forward P/E ratio of 45.0 and a beta of 1.971. Over the past year, the stock has seen a low of $32.21 and a high of $170.87. Its 50-day moving average is $54.79, while the 200-day moving average is $99.42. GeneDx maintains a current ratio of 3.088 and a quick ratio of 2.825.

Recent Earnings

GeneDx Holdings Corp. reported revenue of $442.7 million with a growth rate of 17.4%. However, the company is not currently profitable, posting a net margin of -17.6% and a return on equity of -30.4%. The next earnings report is expected on July 28, 2026.

Analysts Set New Price Targets

On June 23, 2026, Piper Sandler maintained its 'buy' rating for GeneDx Holdings with a price target of $63.0. Other firms like Canaccord Genuity and Wells Fargo also maintained 'buy' ratings in May, with targets of $75.0. The consensus among analysts is a 'strong buy', with a mean target price of $77.0 based on nine analyst opinions.

About GeneDx Holdings Corp.

GeneDx Holdings Corp., headquartered in Stamford, Connecticut, specializes in genetic testing services. The company focuses on pediatric and rare disease diagnostics, utilizing whole exome and genome sequencing. It also develops AI-based platforms for next-generation sequencing analysis and clinical reporting. Founded in 2000, GeneDx employs around 1,300 people and is led by CEO Kevin Feeley, CPA.

Bottom Line

Joshua Ruch's recent purchase of GeneDx Holdings shares signals continued interest in the company from insiders. Investors keep a close eye on such transactions for insights into the company's potential. GeneDx's stock performance and analyst ratings highlight the market's expectations, although 13F filings and insider transactions are backward-looking and may not reflect current positions.